News

OPIVU Cosmetics announces end of trademark infringement battle with OPI Cosmetics

BY Antoinette Alexander

DANVILLE, Calif. — Emerging beauty brand OPIVU Cosmetics has announced the end of a nearly four-year trademark infringement battle with Coty’s OPI Cosmetics.

According to OPIVU Cosmetics, the issue began in October 2010 when OPIVU filed for its trademark "OPIVU Cosmetics." Upon discovering OPIVU's new application, OPI — which had recently edited its own trademark to include the word "cosmetics" following a buyout from Coty Holdings — immediately filed an opposition to the mark ordering OPIVU to halt their marketing under the new trademark.

In 2012, OPIVU CEO Moses Gora called Vince Engel, an advertising professional who has worked with such brands as Buxum, Nike and the San Francisco 49ers, to give the brand a complete makeover. Together, OPIVU worked with Engel and a team of grad students from San Francisco's Academy of Art University's Advertising School to rebrand OPIVU without changing the name.

Furthermore, in May 2014, Gora emailed OPI's founder George Sheffer requesting advice on how to engage in negotiation outside of the courtroom. Sheffer forwarded the letter to the corporation's legal team, and on Aug. 11, the opposition was finally settled, OPIVU stated.

With the trademark opposition now in the past, OPIVU is now looking to grow its brand. The company recently created a limited-edition lip gloss for an Allure magazine "Best of Beauty" event and is currently talking with retailers to expand distribution.

The company is named after Opulence For You (Op. IV U), the salon at which founder Susanna Stroberg got her start. The brand focuses on providing all-natural, hypoallergenic makeup for the “global girl.”
 

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

HRG to present front-end merchandising strategies to the Pharmacy School at Concordia University Wisconsin

BY Michael Johnsen

WAUKESHA, Wis. — Hamacher Resource Group last week announced co-owner Tom Boyer will present a session about pharmacy layout, design and merchandising principles on Sept. 2 to third-year students in the Pharmacy School at Concordia University Wisconsin. It’s the third year Boyer will present these topics to help students understand the importance and profit potential of the pharmacy front-end. The presentation covers merchandising guidelines to create a shopping experience that improves customer satisfaction and boosts front-of-store sales.
 
“This is an integral topic within the marketing section of our Pharmacy Management and Leadership class, which is required of all pharmacy students,” stated Dean Arneson, Dean of the School of Pharmacy Science at Concordia. “Students who have attended this special session with Tom in the past have much appreciated his perspective, and we are excited to offer a new group of students a similar opportunity.”
 
Boyer also has given similar presentations at other pharmacy schools across the country, urging future pharmacists to pay attention to their customers’ needs and design their front-end to encourage a pleasant shopping experience with a healthcare-centric approach.
 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Acura Pharmaceuticals awarded $300,000 grant to develop Rx abuse deterrent technology

BY Michael Johnsen

PALATINE, Ill. — Acura Pharmaceuticals last week announced that it has been awarded a $300,000 grant by the National Institute On Drug Abuse of the National Institutes of Health to fund Phase I development of Acura's new, early stage Limitx abuse deterrent technology. The Grant is based on a proposal submitted by the company to advance the development of a self-regulating hydromorphone tablet intended to deter abuse by excess oral consumption of the tablets.
 
Under the terms of the grant, the company must complete Phase I development by Feb. 28, 2015. Phase I of the project is intended to optimize the formulation in preparation for clinical testing in Phase II. 
 
NIDA funding of Phase II development, for which an application has already been submitted, will be contingent upon assessment by NIDA of the Phase I progress report and determination that the Phase I milestones were achieved, review and approval of other documents necessary for continuation and availability of funds. 
keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

POLLS

Which area of the industry do you think Amazon’s entry would shake up the most?